First-line chemoimmunotherapy versus chemotherapy in PD-L1-negative patients with non-small-cell lung cancer
Immunotherapy, Ahead of Print. (Source: Immunotherapy)
Source: Immunotherapy - June 13, 2022 Category: Allergy & Immunology Authors: Daniele Mengato Luca Cancanelli Melania Rivano Marco Chiumente Lorenzo Di Spazio Andrea Messori Source Type: research
Immune checkpoint inhibitors in luminal gastrointestinal malignancies: going beyond MSI-H/dMMR, TMB and PD-L1
Immunotherapy, Ahead of Print. (Source: Immunotherapy)
Source: Immunotherapy - June 13, 2022 Category: Allergy & Immunology Authors: Daniel S Lefler Adam E Snook Babar Bashir Source Type: research
Development of hepatitis triggered by SARS-CoV-2 vaccination in patient with cancer during immunotherapy: a case report
Immunotherapy, Ahead of Print. (Source: Immunotherapy)
Source: Immunotherapy - June 13, 2022 Category: Allergy & Immunology Authors: Angioletta Lasagna Marco Vincenzo Lenti Irene Cassaniti Paolo Sacchi Source Type: research
Indications and effects of biological agents in the treatment of noninfectious uveitis
Immunotherapy, Ahead of Print. (Source: Immunotherapy)
Source: Immunotherapy - June 13, 2022 Category: Allergy & Immunology Authors: Bowen Li Li Yang Feng Bai Bainan Tong Xiaoli Liu Source Type: research
Complete response and survival outcomes in patients with advanced cancer on immune checkpoint inhibitors
Immunotherapy, Ahead of Print. (Source: Immunotherapy)
Source: Immunotherapy - June 9, 2022 Category: Allergy & Immunology Authors: Adi Kartolo Cynthia Yeung Wilma Hopman Andrea S Fung Tara Baetz Francisco E Vera Badillo Source Type: research
Treatment of EAE mice with Treg, G-MDSC and IL-2: a new insight into cell therapy for multiple sclerosis
Immunotherapy, Ahead of Print. (Source: Immunotherapy)
Source: Immunotherapy - June 9, 2022 Category: Allergy & Immunology Authors: Mohammad Mehdi Ghorbani Touraj Farazmandfar Saeid Abediankenari Hadi Hassannia Zahra Maleki Majid Shahbazi Source Type: research
Therapeutics to tackle Omicron outbreak
Immunotherapy, Ahead of Print. (Source: Immunotherapy)
Source: Immunotherapy - June 9, 2022 Category: Allergy & Immunology Authors: Vivek P Chavda Eswara Naga Hanuma Kumar Ghali Murali M Yallapu Vasso Apostolopoulos Source Type: research
Hypermutation as a potential predictive biomarker of immunotherapy efficacy in high-grade gliomas: a broken dream?
Immunotherapy, Ahead of Print. (Source: Immunotherapy)
Source: Immunotherapy - June 7, 2022 Category: Allergy & Immunology Authors: Lidia Gatto Enrico Franceschi Alicia Tosoni Vincenzo Di Nunno Stefania Bartolini Alba Ariela Brandes Source Type: research
Neoadjuvant chemoimmunotherapy in early triple-negative breast cancer: a new kid on the block?
Immunotherapy, Ahead of Print. (Source: Immunotherapy)
Source: Immunotherapy - June 1, 2022 Category: Allergy & Immunology Authors: Alessandro Rizzo Gennaro Palmiotti Source Type: research
Barriers and solutions to improve access for chimeric antigen receptor therapies
Immunotherapy, Ahead of Print. (Source: Immunotherapy)
Source: Immunotherapy - May 27, 2022 Category: Allergy & Immunology Authors: Sachin Kamal-Bahl Justin T Puckett Indranil Bagchi Ellen Miller-Sonet Scott F Huntington Source Type: research
Combined application of bevacizumab and PD-1 blockade displays durable treatment effects by increasing the infiltration and cytotoxic function of CD8+ T cells in lung cancer
Immunotherapy, Ahead of Print. (Source: Immunotherapy)
Source: Immunotherapy - May 16, 2022 Category: Allergy & Immunology Authors: Yanxia Liu Tongmei Zhang Lina Zhang Cong Zhao Zhiyun Zhang Ziyu Wang Meng Gu Weiying Li Baolan Li Source Type: research
A review of the totality of evidence in the development of ABP 798, a rituximab biosimilar
Immunotherapy, Ahead of Print. (Source: Immunotherapy)
Source: Immunotherapy - May 11, 2022 Category: Allergy & Immunology Authors: Patrick Cobb Dietger Niederwieser Stanley Cohen Caroline Hamm Gerd Burmester Neungseon Seo Sonya G Lehto Vladimir Hanes Source Type: research
A review of phase III clinical trials of US FDA-approved biologic therapies for chronic rhinosinusitis with nasal polyposis
Immunotherapy,Volume 14, Issue 8, Page 655-662, June 2022. (Source: Immunotherapy)
Source: Immunotherapy - May 5, 2022 Category: Allergy & Immunology Authors: Matthew J Lelegren Sam Y Son Joseph K Han Kent K Lam Source Type: research
Current immunosuppression strategies in pediatric heart transplant
Immunotherapy, Ahead of Print. (Source: Immunotherapy)
Source: Immunotherapy - May 5, 2022 Category: Allergy & Immunology Authors: Konstantinos S Mylonas Ioanna Soukouli Dimitrios V Avgerinos John N Boletis Source Type: research
A review of phase III clinical trials of US FDA-approved biologic therapies for chronic rhinosinusitis with nasal polyposis
Immunotherapy, Ahead of Print. (Source: Immunotherapy)
Source: Immunotherapy - May 5, 2022 Category: Allergy & Immunology Authors: Matthew J Lelegren Sam Y Son Joseph K Han Kent K Lam Source Type: research
